| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SLDB | Common Stock | Award | $5M | +904K | +28.88% | $5.53 | 4.03M | Jan 11, 2024 | See footnotes | F1, F2, F3, F4, F5, F6, F7, F8 |
| Id | Content |
|---|---|
| F1 | On January 8, 2024, BCLS II Equity Opportunities, LP ("BCLS II Equity") entered into a securities purchase agreement with the Issuer pursuant to which the Issuer agreed to issue and sell 904,160 shares of Common Stock to BCLS II Equity at a price of $5.53 per share (the "January 2024 Private Placement"). The January 2024 Private Placement closed on January 11, 2024. BCLS II Equity and BCLS II Equity Opportunities GP, LLC ("BCLS II Equity GP"), its general partner, plan to file a Form 3 with the Securities and Exchange Commission in connection with the acquisition of shares of Common Stock by BCLS II Equity in the January 2024 Private Placement. |
| F2 | Represents 528,660 shares of Common Stock held directly by BCLS SB Investco, LP ("BCLS SB"), 267,257 shares of Common Stock held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS Fund II"), 2,301,955 shares of Common Stock held directly by BCLS II Investco, LP ("BCLS II Investco"), 904,160 shares of Common Stock held directly by BCLS II Equity and 32,550 shares of Common Stock held directly by BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS SB, BCLS Fund II, BCLS II Investco and BCLS II Equity, the "Bain Capital Life Sciences Entities"), after giving effect to the closing of the January 2024 Private Placement. |
| F3 | Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS SB. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS SB. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
| F4 | Bain Capital Life Sciences Investors II, LLC ("BCLSI II") is the general partner of BCLS Fund II. As a result, BCLSI II may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund II. BCLSI II disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
| F5 | BCLS II Investco (GP), LLC ("BCLS II Investco GP"), whose managing member is BCLS Fund II, is the general partner of BCLS II Investco. As a result, each of BCLSI II, BCLS Fund II and BCLS II Investco GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS II Investco. Each of BCLSI II, BCLS Fund II and BCLS II Investco GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
| F6 | BCLS Fund II is the manager of BCLS II Equity GP. As a result, each of BCLSI II and BCLS Fund II may be deemed to share voting and dispositive power with respect to the securities held by BCLS II Equity. Each of BCLSI II and BCLS Fund II disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
| F7 | Boylston Coinvestors, LLC is the general partner of BCIPLS. |
| F8 | Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the general partner of BCLSP, (ii) is the manager of BCLSI II and (iii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |